Technical Analysis for ADAP - Adaptimmune Therapeutics plc

Grade Last Price % Change Price Change
grade B 13.31 0.45% 0.06
ADAP closed up 0.45 percent on Friday, May 25, 2018, on 35 percent of normal volume.

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical ADAP trend table...

Date Alert Name Type % Chg
May 25 Narrow Range Bar Range Contraction 0.00%
May 25 Inside Day Range Contraction 0.00%
May 25 Up 3 Days in a Row Strength 0.00%
May 25 Up 4 Days in a Row Strength 0.00%
May 25 Up 5 Days in a Row Strength 0.00%
May 24 Spinning Top Other 0.45%
May 24 Up 3 Days in a Row Strength 0.45%
May 24 Up 4 Days in a Row Strength 0.45%
May 24 Up 5 Days in a Row Strength 0.45%
May 23 Up 3 Days in a Row Strength 0.83%

Older signals for ADAP ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its T-cell receptor platform. Its platform enables to identify cancer targets in the form of peptides, which are short sequences of amino acids; find and genetically engineer T-cell receptors (TCR); and produce TCR therapeutic candidates for administration to patients. The company's lead product candidate includes NY-ESO, a cancer antigen, which is in Phase I/II clinical trials for the treatment of patients with solid tumors and hematological malignancies, including synovial sarcoma, multiple myeloma, melanoma, ovarian cancer, and esophageal cancer, as well as for non-small cell lung cancer. It is also developing MAGE A-10 TCR that is in preclinical stage for the treatment of breast and lung cancer, and other solid tumors, as well as a TCR therapeutic candidate directed to Alpha Fetoprotein. The company was founded in 2014 and is headquartered in Abingdon, the United Kingdom.
Is ADAP a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 14.625
52 Week Low 4.28
Average Volume 541,314
200-Day Moving Average 8.825
50-Day Moving Average 12.1226
20-Day Moving Average 12.881
10-Day Moving Average 12.646
Average True Range 0.7291
ADX 33.63
+DI 22.99
-DI 10.96
Chandelier Exit (Long, 3 ATRs ) 12.4377
Chandelier Exit (Short, 3 ATRs ) 14.0373
Upper Bollinger Band 13.7703
Lower Bollinger Band 11.9917
Percent B (%b) 0.74
BandWidth 13.807934
MACD Line 0.2356
MACD Signal Line 0.2625
MACD Histogram -0.0269
Fundamentals Value
Market Cap 1.24 Billion
Num Shares 93.5 Million
EPS -0.99
Price-to-Earnings (P/E) Ratio -13.44
Price-to-Sales 39.39
Price-to-Book 2.97
PEG Ratio 0.17
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 13.82
Resistance 3 (R3) 13.78 13.57 13.74
Resistance 2 (R2) 13.57 13.44 13.59 13.71
Resistance 1 (R1) 13.44 13.36 13.51 13.48 13.68
Pivot Point 13.23 13.23 13.26 13.25 13.23
Support 1 (S1) 13.10 13.10 13.17 13.14 12.94
Support 2 (S2) 12.89 13.02 12.91 12.91
Support 3 (S3) 12.76 12.89 12.89
Support 4 (S4) 12.80